Home › Companies › Corcept Therapeutics Incorporated › 2025-2026
Compiled from SEC Form N-PX filings and Corcept Therapeutics Incorporated’s Form 8-K, filed 2026-05-28 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Corcept Therapeutics Incorporated in the interactive database Compare manager voting policies
These tallies are Corcept Therapeutics Incorporated’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Gregg Alton | 67,977,943 | -- | -- | 9,316,514 | 15,975,718 | Majority: yes |
| Elect Director: G. Leonard Baker, Jr. | 64,912,506 | -- | -- | 12,381,951 | 15,975,718 | Majority: yes |
| Elect Director: Joseph K. Belanoff, M.D. | 76,965,512 | -- | -- | 328,945 | 15,975,718 | Majority: yes |
| Elect Director: David L. Mahoney | 51,078,278 | -- | -- | 26,216,179 | 15,975,718 | Majority: yes |
| Elect Director: Joshua M. Murray | 76,753,606 | -- | -- | 540,851 | 15,975,718 | Majority: yes |
| Elect Director: Kimberly Park | 70,288,833 | -- | -- | 7,005,624 | 15,975,718 | Majority: yes |
| Elect Director: Daniel N. Swisher, Jr. | 67,594,098 | -- | -- | 9,700,359 | 15,975,718 | Majority: yes |
| Elect Director: James N. Wilson | 72,730,017 | -- | -- | 4,564,440 | 15,975,718 | Majority: yes |
| Proposal 2 - The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. | 92,656,473 | 569,010 | 44,692 | -- | -- | Majority: yes |
| Proposal 3 - The compensation of named executive officers was approved, on an advisory basis. | 72,511,429 | 4,560,385 | 222,643 | -- | 15,975,718 | Majority: yes |
| Proposal 4 - The amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan was approved. | 53,163,364 | 23,867,363 | 263,730 | -- | 15,975,718 | Majority: yes |
Source: Corcept Therapeutics Incorporated, Form 8-K, filed with the SEC on 2026-05-28 — read the filing on EDGAR.
Each item below shows how the 360 asset managers that disclosed a Corcept Therapeutics Incorporated vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Corcept Therapeutics Incorporated’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 12 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Proposal 3 - The compensation of named executive officers was approved, on an advisory basis.”): 72,511,429 for, 4,560,385 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 68% for, 4% against (73% of the company cast a for/against vote).
The 358 asset managers below cast 95% of the shares they voted on this item FOR (51,982,739 for, 2,665,880 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 10,905,781 | 25,148 | 0 | 0 | For |
| Vanguard | 9,904,355 | 41,683 | 1 | 0 | For |
| Fidelity | 8,403,405 | 0 | 0 | 0 | For |
| State Street | 2,784,323 | 3,486 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,717,258 | 0 | 0 | 0 | For |
| First Trust | 2,194,958 | 0 | 0 | 0 | For |
| Charles Schwab | 2,144,568 | 0 | 0 | 0 | For |
| Renaissance | 966,044 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 952,575 | 0 | 0 | 0 | For |
| Apollon Wealth Management, LLC | 880,534 | 0 | 0 | 0 | For |
| Northern Trust | 613,044 | 8,248 | 0 | 0 | For |
| Dimensional | 553,301 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 455,248 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 425,062 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 364,102 | 0 | 0 | Against |
| CANADA PENSION PLAN INVESTMENT BOARD | 322,401 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 268,590 | 0 | 0 | 0 | For |
| Janus Henderson | 242,570 | 0 | 0 | 0 | For |
| Jackson National | 36,347 | 198,027 | 0 | 0 | Against |
| Goldman Sachs | 233,954 | 0 | 0 | 0 | For |
| Allspring | 230,753 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN NATIONAL ASSOCIATION | 0 | 226,566 | 0 | 0 | Against |
| T. Rowe Price | 220,018 | 0 | 0 | 0 | For |
| BNY Mellon | 48,715 | 161,435 | 0 | 0 | Against |
| Cerity Partners LLC | 204,244 | 0 | 0 | 0 | For |
Showing the 25 largest of 358 asset managers. See all 358 in the interactive database.
Combines 6 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: Joseph K. Belanoff, M.D.”): 76,965,512 for, 328,945 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 73% for, 0.4% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (30,619,738 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,198,747 | 0 | 2 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,218,560 | 0 | 0 | 0 | For |
| First Trust | 2,182,373 | 0 | 0 | 0 | For |
| State Street | 1,564,463 | 0 | 130 | 0 | For |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 353,405 | 0 | 0 | 0 | For |
| Jackson National | 234,374 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 181,631 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 177,736 | 0 | 0 | 0 | For |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 127,995 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 121,285 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 75,759 | 0 | 0 | 0 | For |
| AQR | 74,174 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: Gregg Alton”): 67,977,943 for, 9,316,514 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 64% for, 9% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (27,085,523 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,175,350 | 0 | 23,399 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,208,686 | 0 | 9,874 | 0 | For |
| First Trust | 0 | 0 | 2,182,373 | 0 | Abstain |
| State Street | 1,548,980 | 0 | 15,613 | 0 | For |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 353,405 | 0 | Abstain |
| Jackson National | 198,027 | 0 | 36,347 | 0 | For |
| Columbia Threadneedle | 181,631 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 0 | 177,736 | 0 | Abstain |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 53,708 | 0 | 74,287 | 0 | Abstain |
| Janus Detroit Street Trust | 0 | 0 | 121,285 | 0 | Abstain |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 75,759 | 0 | Abstain |
| AQR | 0 | 0 | 74,174 | 0 | Abstain |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: G. Leonard Baker, Jr.”): 64,912,506 for, 12,381,951 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 61% for, 12% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (25,344,975 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,175,331 | 0 | 23,418 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,208,686 | 0 | 9,874 | 0 | For |
| First Trust | 0 | 0 | 2,182,373 | 0 | Abstain |
| State Street | 4,014 | 0 | 1,560,579 | 0 | Abstain |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 353,405 | 0 | Abstain |
| Jackson National | 198,027 | 0 | 36,347 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 181,631 | 0 | Abstain |
| BOSTON TRUST WALDEN FUNDS | 0 | 0 | 177,736 | 0 | Abstain |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 53,708 | 0 | 74,287 | 0 | Abstain |
| Janus Detroit Street Trust | 0 | 0 | 121,285 | 0 | Abstain |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 75,759 | 0 | Abstain |
| AQR | 0 | 0 | 74,174 | 0 | Abstain |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: David L. Mahoney”): 51,078,278 for, 26,216,179 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 48.2% for, 25% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (14,743,201 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,190,074 | 0 | 8,674 | 0 | For |
| BlackRock | 66,185 | 0 | 8,117,935 | 0 | Abstain |
| Fidelity | 2,695,332 | 0 | 2,523,228 | 0 | For |
| First Trust | 0 | 0 | 2,182,373 | 0 | Abstain |
| State Street | 4,014 | 0 | 1,560,579 | 0 | Abstain |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 353,405 | 0 | Abstain |
| Jackson National | 198,027 | 0 | 36,347 | 0 | For |
| Columbia Threadneedle | 181,631 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 0 | 177,736 | 0 | Abstain |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 53,708 | 0 | 74,287 | 0 | Abstain |
| Janus Detroit Street Trust | 0 | 0 | 121,285 | 0 | Abstain |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 75,759 | 0 | Abstain |
| AQR | 0 | 0 | 74,174 | 0 | Abstain |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 5,140 | 0 | 57,989 | 0 | Abstain |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: Joshua M. Murray”): 76,753,606 for, 540,851 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 72% for, 0.6% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (30,619,866 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,198,745 | 0 | 4 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,218,560 | 0 | 0 | 0 | For |
| First Trust | 2,182,373 | 0 | 0 | 0 | For |
| State Street | 1,564,593 | 0 | 0 | 0 | For |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 353,405 | 0 | 0 | 0 | For |
| Jackson National | 234,374 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 181,631 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 177,736 | 0 | 0 | 0 | For |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 127,995 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 121,285 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 75,759 | 0 | 0 | 0 | For |
| AQR | 74,174 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: Kimberly Park”): 70,288,833 for, 7,005,624 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 66% for, 7% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (28,376,570 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,183,863 | 0 | 14,886 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,218,560 | 0 | 0 | 0 | For |
| First Trust | 2,182,373 | 0 | 0 | 0 | For |
| State Street | 19,626 | 0 | 1,544,967 | 0 | Abstain |
| Charles Schwab | 1,020,865 | 0 | 217 | 0 | For |
| Dimensional | 353,405 | 0 | 0 | 0 | For |
| Jackson National | 234,374 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 181,631 | 0 | Abstain |
| BOSTON TRUST WALDEN FUNDS | 0 | 0 | 177,736 | 0 | Abstain |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 127,995 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 121,285 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 75,759 | 0 | 0 | 0 | For |
| AQR | 74,174 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 0 | 0 | 71,812 | 0 | Abstain |
| Putnam | 0 | 0 | 71,394 | 0 | Abstain |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: Daniel N. Swisher, Jr.”): 67,594,098 for, 9,700,359 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 64% for, 9% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (27,092,897 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,190,183 | 0 | 8,566 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,208,686 | 0 | 9,874 | 0 | For |
| First Trust | 0 | 0 | 2,182,373 | 0 | Abstain |
| State Street | 1,548,980 | 0 | 15,613 | 0 | For |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 353,405 | 0 | Abstain |
| Jackson National | 198,027 | 0 | 36,347 | 0 | For |
| Columbia Threadneedle | 181,631 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 0 | 177,736 | 0 | Abstain |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 53,708 | 0 | 74,287 | 0 | Abstain |
| Janus Detroit Street Trust | 0 | 0 | 121,285 | 0 | Abstain |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 75,759 | 0 | Abstain |
| AQR | 0 | 0 | 74,174 | 0 | Abstain |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Elect Director: James N. Wilson”): 72,730,017 for, 4,564,440 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 69% for, 4% withheld (73% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (28,664,048 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,183,883 | 0 | 14,866 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,218,560 | 0 | 0 | 0 | For |
| First Trust | 2,182,373 | 0 | 0 | 0 | For |
| State Street | 19,496 | 0 | 1,545,097 | 0 | Abstain |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 353,405 | 0 | 0 | 0 | For |
| Jackson National | 234,374 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 181,631 | 0 | Abstain |
| BOSTON TRUST WALDEN FUNDS | 0 | 0 | 177,736 | 0 | Abstain |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 127,995 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 121,285 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 75,759 | 0 | 0 | 0 | For |
| AQR | 74,174 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Proposal 2 - The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”): 92,656,473 for, 569,010 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 87% for, 0.6% against (88% of the company cast a for/against vote).
The 93 asset managers below cast 99.9% of the shares they voted on this item FOR (30,657,444 for, 28,426 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,183,912 | 14,837 | 0 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 5,218,560 | 0 | 0 | 0 | For |
| First Trust | 2,182,373 | 0 | 0 | 0 | For |
| State Street | 1,564,463 | 130 | 0 | 0 | For |
| Charles Schwab | 1,021,083 | 0 | 0 | 0 | For |
| Dimensional | 353,405 | 0 | 0 | 0 | For |
| Jackson National | 234,374 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 181,631 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 177,736 | 0 | 0 | 0 | For |
| TIAA | 176,851 | 0 | 0 | 0 | For |
| Royce | 132,800 | 0 | 0 | 0 | For |
| Principal | 127,995 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 121,285 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 82,385 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 75,759 | 0 | 0 | 0 | For |
| AQR | 74,174 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 71,812 | 0 | 0 | 0 | For |
| Putnam | 71,394 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 70,000 | 0 | 0 | 0 | For |
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Invesco | 63,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 2 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Proposal 4 - The amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan was approved.”): 53,163,364 for, 23,867,363 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 50.2% for, 23% against (73% of the company cast a for/against vote).
The 92 asset managers below cast 60% of the shares they voted on this item FOR (18,174,775 for, 12,291,747 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,131,617 | 4,067,130 | 1 | 0 | For |
| BlackRock | 8,184,120 | 0 | 0 | 0 | For |
| Fidelity | 2,540,525 | 2,678,035 | 0 | 0 | Against |
| First Trust | 0 | 2,182,373 | 0 | 0 | Against |
| State Street | 1,546,060 | 18,533 | 0 | 0 | For |
| Charles Schwab | 664 | 1,020,419 | 0 | 0 | Against |
| Dimensional | 0 | 353,405 | 0 | 0 | Against |
| Jackson National | 0 | 234,374 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 181,631 | 0 | 0 | Against |
| BOSTON TRUST WALDEN FUNDS | 177,736 | 0 | 0 | 0 | For |
| TIAA | 0 | 176,851 | 0 | 0 | Against |
| Royce | 0 | 0 | 132,800 | 0 | Abstain |
| Principal | 53,708 | 74,287 | 0 | 0 | Against |
| Janus Detroit Street Trust | 0 | 121,285 | 0 | 0 | Against |
| RBB FUND, INC. | 115,882 | 0 | 0 | 0 | For |
| JPMorgan | 101,479 | 0 | 0 | 0 | For |
| EA Series Trust | 97,568 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 82,385 | 0 | 0 | Against |
| OLD WESTBURY FUNDS INC | 0 | 75,759 | 0 | 0 | Against |
| AQR | 0 | 74,174 | 0 | 0 | Against |
| Brown Capital Management Mutual Funds | 0 | 71,812 | 0 | 0 | Against |
| Putnam | 0 | 71,394 | 0 | 0 | Against |
| HUSSMAN INVESTMENT TRUST | 0 | 70,000 | 0 | 0 | Against |
| Invesco | 0 | 63,836 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 63,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.
69% Majority: yes · of votes cast
Corcept Therapeutics Incorporated’s own tally for this item (“Proposal 4 - The amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan was approved.”): 53,163,364 for, 23,867,363 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,966,000 outstanding shares: 50.2% for, 23% against (73% of the company cast a for/against vote).
The 4 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 17,394 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 0 | 0 | 0 | 0 | Not Voted |
| Maj Invest Holding A/S | 0 | 11,544 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 0 | 4,200 | 0 | 0 | Against |
| FORUM FUNDS | 0 | 1,650 | 0 | 0 | Against |
Ranked by the number of Corcept Therapeutics Incorporated shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 105,966,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 10.32% |
| 2 | Vanguard | 9.39% |
| 3 | Fidelity | 7.93% |
| 4 | State Street | 2.63% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.56% |
| 6 | First Trust | 2.07% |
| 7 | Charles Schwab | 2.02% |
| 8 | Renaissance | 0.91% |
| 9 | MPM BioImpact LLC | 0.90% |
| 10 | Apollon Wealth Management, LLC | 0.83% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 11.47% | 13F |
| Vanguard Group | 8.96% | 13F |
| INGALLS & SNYDER LLC | 6.85% | 13G |
| Joseph K. Belanoff, M.D. | 6.36% | DEF14A |
| G. Leonard Baker, Jr. | 5.35% | DEF14A |
| Renaissance Technologies LLC | 4.97% | 13G |
| State Street | 3.02% | 13F |
| FMR (Fidelity) | 3.01% | 13F |
| James N. Wilson | 2.82% | DEF14A |
| Geode Capital | 2.56% | 13F |
Percentages above are of 105,966,000 shares outstanding, as reported by Corcept Therapeutics Incorporated on its Form 10-K dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Corcept Therapeutics Incorporated’s 10-K dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Corcept Therapeutics Incorporated's shareholder meeting held 2026-05-21, in the 2025-2026 proxy season, 360 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,066 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the company's named executive officers as… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Corcept Therapeutics Incorporated's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-28.
Corcept Therapeutics Incorporated proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).